Trial · NCT00567268
Adverse events35
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 35
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Decreased activity | Psychiatric disorders | Gabapentin 200, 300, 400 mg Tablets | 8 | 1,144 | 8 |
| other | Ataxia | Nervous system disorders | Gabapentin 200, 300, 400 mg Tablets | 6 | 1,144 | 6 |
| other | Somnolence | Nervous system disorders | Gabapentin 200, 300, 400 mg Tablets | 137 | 1,144 | 137 |
| other | Headache | Nervous system disorders | Gabapentin 200, 300, 400 mg Tablets | 6 | 1,144 | 6 |
| other | Dizziness | Nervous system disorders | Gabapentin 200, 300, 400 mg Tablets | 40 | 1,144 | 40 |
| other | Hepatic function abnormal | Hepatobiliary disorders | Gabapentin 200, 300, 400 mg Tablets | 6 | 1,144 | 6 |
| other | Malaise | General disorders | Gabapentin 200, 300, 400 mg Tablets | 8 | 1,144 | 8 |
| other | Gamma-glutamyltransferase increased | Investigations | Gabapentin 200, 300, 400 mg Tablets | 11 | 1,144 | 11 |
| other | White blood cell count decreased | Investigations | Gabapentin 200, 300, 400 mg Tablets | 7 | 1,144 | 7 |
| other | Nausea | Gastrointestinal disorders | Gabapentin 200, 300, 400 mg Tablets | 6 | 1,144 | 6 |
| other | Convulsion | Nervous system disorders | Gabapentin 200, 300, 400 mg Tablets | 13 | 1,144 | 13 |
| serious | Anaemia | Blood and lymphatic system disorders | Gabapentin 200, 300, 400 mg Tablets | 2 | 1,144 | 2 |
| serious | Pancytopenia | Blood and lymphatic system disorders | Gabapentin 200, 300, 400 mg Tablets | 1 | 1,144 | 1 |
| serious | Sepsis | Infections and infestations | Gabapentin 200, 300, 400 mg Tablets | 2 | 1,144 | 2 |
| serious | Pneumonia | Infections and infestations | Gabapentin 200, 300, 400 mg Tablets | 2 | 1,144 | 2 |
| serious | Neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Gabapentin 200, 300, 400 mg Tablets | 1 | 1,144 | 1 |
| serious | Brain neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Gabapentin 200, 300, 400 mg Tablets | 4 | 1,144 | 4 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Gabapentin 200, 300, 400 mg Tablets | 1 | 1,144 | 1 |
| serious | Nasal sinus cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Gabapentin 200, 300, 400 mg Tablets | 1 | 1,144 | 1 |
| serious | Hypophagia | Metabolism and nutrition disorders | Gabapentin 200, 300, 400 mg Tablets | 1 | 1,144 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00567268/events